Investigating therapeutic efficacy of Lactobacillus salivarius GZLC1 on colitis by examining its effects on intestinal fungi, antioxidant capacity, and inflammatory response in mice
In: Beneficial MicrobesSearch for other papers by J. Ma in
Current site
Google Scholar
Search for other papers by D. Wu in
Current site
Google Scholar
Search for other papers by M. Liu in
Current site
Google Scholar
Search for other papers by C. Xu in
Current site
Google Scholar
Search for other papers by Q. He in
Current site
Google Scholar
Search for other papers by M. Wang in
Current site
Google Scholar
Search for other papers by F.A. Kiani in
Current site
Google Scholar
Search for other papers by M.S. Rafiq in
Current site
Google Scholar
Search for other papers by K. Mehmood in
Current site
Google Scholar
Search for other papers by D. Fouad in
Current site
Google Scholar
Search for other papers by F.S. Ataya in
Current site
Google Scholar
Search for other papers by K. Li in
Current site
Google Scholar
Abstract
We investigated the therapeutic potential of Lactobacillus salivarius in colitis mice, and the mice were randomly allocated into three groups with each consisting of 10 mice (n = 10): a control group (CSG), a DSS-induced colitis model group (DSG), and a L. salivarius intervention group (LSG). The intervention group received daily oral administration of L. salivarius for seven consecutive days. Compared to the DSS model group, mice receiving L. salivarius exhibited significantly reduced weight loss, lower DAI scores, lessened colon shortening, and improved histopathological profiles, indicating a substantial reduction in inflammatory damage. Additionally, ITS sequencing revealed that L. salivarius significantly influenced the composition of the intestinal fungal community, decreasing the abundance of pathogenic fungi, such as Candida species, by approximately 40%, and restoring fungal homeostasis by reducing the Basidiomycota/Ascomycota ratio. Moreover, L. salivarius effectively alleviated DSS-induced oxidative stress by lowering serum MDA levels while enhancing the activity of SOD and GSH-Px. Furthermore, the probiotic intervention resulted in 30-40% reduction in pro-inflammatory factors (TNF-α, IL-6, and IL-1β) and an increase in the anti-inflammatory factor IL-10 levels, suggesting a pronounced anti-inflammatory effect. In conclusion, L. salivarius exerts significant protective effects against DSS-induced colitis by modulating the gut fungal community, mitigating oxidative stress, and suppressing inflammatory responses. This study is novel in that few probiotic studies have investigated the impact of L. salivarius on gut fungi in DSS-induced colitis. These findings highlight its potential as a therapeutic candidate for managing inflammatory bowel disease.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Akiyama, S., Nishijima, S., Kojima, Y., Kimura, M., Ohsugi, M., Ueki, K., Mizokami, M., Hattori, M., Tsuchiya, K., Uemura, N., Kawai, T., Bork, P. and Nagata, N., 2024. Multi-biome analysis identifies distinct gut microbial signatures and their crosstalk in ulcerative colitis and Crohn’s disease. Nature Communications 15(1): 10291. https://doi.org/10.1038/s41467-024-54797-8
-
Banz, M., Stallmach, A., Gaßler, N., Schulze, P.C., Fritzenwanger, M., Cornely, O., Kurzai, O. and Pletz, M.W., 2024. Fatal pulmonary hemorrhage, pneumothorax and skin necrosis caused by IRIS to an Aspergillus flavus infection in a young patient with metamizole associated agranulocytosis. Infection 52(2): 685-690. https://doi.org/10.1007/s15010-023-02149-x
-
Chang, L., Wang, C., Peng, J., Song, Y., Zhang, W., Chen, Y., Peng, Q., Li, X., Liu, X. and Lan, Y., 2024. Rattan pepper polysaccharide regulates DSS-induced intestinal inflammation and depressive behavior through microbiota-gut-brain axis. Journal of Agricultural and Food Chemistry 72(1): 437-448. https://doi.org/10.1021/acs.jafc.3c08462
-
Cheng, J., Zhang, Y., Ma, L., Du, W., Zhang, Q., Gao, R., Zhao, X., Chen, Y., Jiang, L., Li, X., Li, B. and Zhou, Y., 2023. Macrophage-derived extracellular vesicles-coated palladium nanoformulations modulate inflammatory and immune homeostasis for targeting therapy of ulcerative colitis. Advanced Science 10(33): e2304002. https://doi.org/10.1002/advs.202304002
-
Chu, X.-Q., Wang, J., Chen, G.-X., Zhang, G.-Q., Zhang, D.-Y. and Cai, Y.-Y., 2018. Overexpression of microRNA-495 improves the intestinal mucosal barrier function by targeting STAT3 via inhibition of the JAK/STAT3 signaling pathway in a mouse model of ulcerative colitis. Pathology – Research and Practice 214(1): 151-162. https://doi.org/10.1016/j.prp.2017.10.003
-
Fumery, M., Singh, S., Dulai, P.S., Gower-Rousseau, C., Peyrin-Biroulet, L. and Sandborn, W.J., 2018. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clinical Gastroenterology and Hepatology 16(3): 343-356.e3. https://doi.org/10.1016/j.cgh.2017.06.016
-
Gou, H.-Z., Zhang, Y.-L., Ren, L.-F., Li, Z.-J. and Zhang, L., 2022. How do intestinal probiotics restore the intestinal barrier? Frontiers in Microbiology 13: 929346. https://doi.org/10.3389/fmicb.2022.929346
-
Gu, P., Liu, R., Yang, Q., Xie, L., Wei, R., Li, J., Mei, F., Chen, T., Zeng, Z., He, Y., Zhou, H., Peng, H., Nandakumar, K.S., Chu, H., Jiang, Y., Gong, W., Chen, Y., Schnabl, B. and Chen, P., 2023. A metabolite from commensal Candida albicans enhances the bactericidal activity of macrophages and protects against sepsis. Cellular and Molecular Immunology 20(10): 1156-1170. https://doi.org/10.1038/s41423-023-01070-5
-
Guo, H., Guo, H., Xie, Y., Chen, Y., Lu, C., Yang, Z., Zhu, Y., Ouyang, Y., Zhang, Y. and Wang, X., 2022. Mo(3)Se(4) nanoparticle with ROS scavenging and multi-enzyme activity for the treatment of DSS-induced colitis in mice. Redox Biology 56: 102441. https://doi.org/10.1016/j.redox.2022.102441
-
Guo, P., Wang, W., Xiang, Q., Pan, C., Qiu, Y., Li, T., Wang, D., Ouyang, J., Jia, R., Shi, M., Wang, Y., Li, J., Zou, J., Zhong, Y., Zhao, J., Zheng, D., Cui, Y., Ma, G. and Wei, W., 2024. Engineered probiotic ameliorates ulcerative colitis by restoring gut microbiota and redox homeostasis. Cell Host Microbe 32(9): 1502-1518.e9. https://doi.org/10.1016/j.chom.2024.07.028
-
Guo, X.Y., Liu, X.J. and Hao, J.Y., 2020. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. Journal of Digestive Diseases 21(3): 147-159. https://doi.org/10.1111/1751-2980.12849
-
Herrlinger, K.R. and Stange, E.F., 2023. Prioritization in inflammatory bowel disease therapy. Expert Review of Gastroenterology and Hepatology 17(8): 753-767. https://doi.org/10.1080/17474124.2023.2240699
-
Hsia, K., Zhao, N., Chung, M., Algarrahi, K., Montaser Kouhsari, L., Fu, M., Chen, H., Singh, S., Michaud, D.S. and Jangi, S., 2023. Alterations in the fungal microbiome in ulcerative colitis. Inflammatory Bowel Disease 29(10): 1613-1621. https://doi.org/10.1093/ibd/izad082
-
Huang, X., Hu, M., Sun, T., Li, J., Zhou, Y., Yan, Y., Xuan, B., Wang, J., Xiong, H., Ji, L., Zhu, X., Tong, T., Ning, L., Ma, Y., Zhao, Y., Ding, J., Guo, Z., Zhang, Y., Fang, J.-Y., Hong, J. and Chen, H., 2023. Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts. Cell Host Microbe 31(11): 1930-1943.e4. https://doi.org/10.1016/j.chom.2023.10.005
-
Jangi, S., Hsia, K., Zhao, N., Kumamoto, C.A., Friedman, S., Singh, S. and Michaud, D.S., 2024. Dynamics of the gut mycobiome in patients with ulcerative colitis. Clinical Gastroenterology and Hepatology 22(4): 821-830.e7. https://doi.org/10.1016/j.cgh.2023.09.023
-
Landskron, G., Dubois-Camacho, K., Orellana-Serradell, O., De la Fuente, M., Parada-Venegas, D., Bitrán, M., Diaz-Jimenez, D., Tang, S., Cidlowski, J.A., Li, X., Molina, H., Gonzalez, C.M., Simian, D., Lubascher, J., Pola, V., Montecino, M., Blokzijl, T., Faber, K.N., González, M.-J., Quera, R. and Hermoso, M.A., 2022. Regulation of the intestinal extra-adrenal steroidogenic pathway component LRH-1 by glucocorticoids in ulcerative colitis. Cells 11(12): 1905. https://doi.org/10.3390/cells11121905
-
Le Berre, C., Honap, S. and Peyrin-Biroulet, L., 2023. Ulcerative colitis. The Lancet 402: 571-584. https://doi.org/10.1016/S0140-6736(23)00966-2
-
Lee, Y.I., Park, Y., Park, S.J., Kim, T.I., Kim, W.H. and Cheon, J.H., 2021. Comparison of long-term outcomes of infliximab versus adalimumab treatment in biologic-naïve patients with ulcerative colitis. Gut Liver 15(2): 232-242. https://doi.org/10.5009/gnl19433
-
Li, C., Peng, K., Xiao, S., Long, Y. and Yu, Q., 2023. The role of Lactobacillus in inflammatory bowel disease: from actualities to prospects. Cell Death Discovery 9(1): 361. https://doi.org/10.1038/s41420-023-01666-w
-
Li, X.V., Leonardi, I., Putzel, G.G., Semon, A., Fiers, W.D., Kusakabe, T., Lin, W.-Y., Gao, I.H., Doron, I., Gutierrez-Guerrero, A., DeCelie, M.B., Carriche, G.M., Mesko, M., Yang, C., Naglik, J.R., Hube, B., Scherl, E.J. and Iliev, I.D., 2022. Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature 603: 672-678. https://doi.org/10.1038/s41586-022-04502-w
-
Li, Y.-Y., Wang, X.-J., Su, Y.-L., Wang, Q., Huang, S.-W., Pan, Z.-F., Chen, Y.-P., Liang, J.-J., Zhang, M.-L., Xie, X.-Q., Wu, Z.-Y., Chen, J.-Y., Zhou, L. and Luo, X., 2022. Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s. Acta Pharmacologica Sinica 43(6): 1495-1507. https://doi.org/10.1038/s41401-021-00781-7
-
Lian, L., Zhang, S., Yu, Z., Ge, H., Qi, S., Zhang, X., Long, L., Xiong, X., Chu, D., Ma, X., Li, X. and Gao, H., 2019. The dietary freeze-dried fruit powder of Actinidia arguta ameliorates dextran sulphate sodium-induced ulcerative colitis in mice by inhibiting the activation of MAPKs. Food and Function 10(9): 5768-5778. https://doi.org/10.1039/c9fo00664h
-
Meng, A., Zhang, X., Pubu, P., Ali, M., Wang, J., Xu, C., Almutairi, M.H. and Li, K., 2024. Protective effect of lentinan against LPS-induced injury in mice via influencing antioxidant enzyme activity, inflammatory pathways and gut microbiota. Pakistan Veterinary Journal 44(3): 647-656. https://doi.org/10.29261/pakvetj/2024.225
-
Oz, H.S., Chen, T.S., McClain, C.J. and de Villiers, W.J.S., 2005. Antioxidants as novel therapy in a murine model of colitis. Journal of Nutritional Biochemistry 16(5): 297-304. https://doi.org/10.1016/j.jnutbio.2004.09.007
-
Peng, S., Xu, C., He, Q., Xu, J., Kiani, F.A., Choudhary, O.P., Idrees, A., Mares, M.M., Wu, Y. and Li, K., 2024. Fucoidan alleviates intestine damage in mice induced by LPS via regulation of microbiota. Pakistan Veterinary Journal 44(2): 517-525. http://dx.doi.org/10.29261/pakvetj/2024.190
-
Pourjafar, H., Ansari, F., Sadeghi, A., Samakkhah, S.A. and Jafari, S.M., 2023. Functional and health-promoting properties of probiotics’ exopolysaccharides; isolation, characterization and applications in the food industry. Critical Reviews in Food Science and Nutrition 63(26): 8194-8225. https://doi.org/10.1080/10408398.2022.2047883
-
Saarenpää, S., Shalev, O., Ashkenazy, H., Carlos, V., Lundberg, D.S., Weigel, D. and Giacomello, S., 2024. Spatial metatranscriptomics resolves host-bacteria-fungi interactomes. Nature Biotechnology 42(9): 1384-1393. https://doi.org/10.1038/s41587-023-01979-2
-
Segal, J.P., LeBlanc, J.-F. and Hart, A.L., 2021. Ulcerative colitis: an update. Clinical Medicine 21(2): 135-139. https://doi.org/10.7861/clinmed.2021-0080
-
Shah, S.C. and Itzkowitz, S.H., 2022. Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology 162(3): 715-730.e3. https://doi.org/10.1053/j.gastro.2021.10.035
-
Steiger, S., Marcucci, V., Desai, V., Zheng, M. and Parker, G., 2022. Refractory fulminant colitis requiring surgical intervention in a patient with ulcerative colitis on atezolizumab therapy for small cell lung cancer: an atypical case. Cureus 14(5): e25437. https://doi.org/10.7759/cureus.25437
-
Tanna, T. and Platt, R.J., 2023. Microbial medics diagnose and treat gut inflammation. Cell Host Microbe 31(2): 164-166. https://doi.org/10.1016/j.chom.2023.01.012
-
Wang, J., Zhang, C., Guo, C. and Li, X., 2019. Chitosan ameliorates DSS-induced ulcerative colitis mice by enhancing intestinal barrier function and improving microflora. International Journal of Molecular Sciences 20(22): 5751. https://doi.org/10.3390/ijms20225751
-
Wang, N., Xiang, Y., Ma, Y., Zhang, P., Zhou, X., Zhu, H., Zhang, Z., Li, Z., Xiao, X., He, M., Mehmood, M.A. and Zhu, H., 2024. Fermented Spirulina platensis alleviated DSS-induced ulcerative colitis by regulating gut microbiota and MyD88/TLR4 signaling pathway. Asian Journal of Agriculture and Biology 2024(1): 2023232. https://doi.org/10.35495/ajab.2023.232
-
Wangchuk, P., Yeshi, K. and Loukas, A., 2024. Ulcerative colitis: clinical biomarkers, therapeutic targets and emerging treatments. Trends in Pharmacological Sciences 45(10): 892-903. https://doi.org/10.1016/j.tips.2024.08.003
-
Wu, Y., Ran, L., Yang, Y., Gao, X., Peng, M., Liu, S., Sun, L., Wan, J., Wang, Y., Yang, K., Yin, M. and Chunyu, W., 2023. Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota. Life Sciences 314: 121312. https://doi.org/10.1016/j.lfs.2022.121312
-
Xie, Q., Zhang, Y., Zhang, Z., Gong, S., Mo, Q. and Li, J., 2024. Characteristics and dynamic changes of gut microbiota in cats with colitis. Pakistan Veterinary Journal 44(2): 414-422. https://doi.org/10.29261/pakvetj/2024.175
-
Xu, C., He, Q., Zhu, Z.Y. and Li, K., 2025. Propolis improves intestinal barrier function against Cryptosporidium parvum via NLRP6 inflammasome. mBio 16(11): e0231725. https://10.1128/mbio.02317-25
-
Zeng, S., Rosati, E., Saggau, C., Messner, B., Chu, H., Duan, Y., Hartmann, P., Wang, Y., Ma, S., Huang, W.J.M., Lee, J., Lee, S.M., Carvalho-Gontijo, R., Zhang, V., Hoffmann, J.P., Kolls, J.K., Raz, E., Brenner, D.A., Kisseleva, T., LeibundGut-Landmann, S., Bacher, P., Stärkel, P. and Schnabl, B., 2023. Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe 31(3): 389-404.e7. https://doi.org/10.1016/j.chom.2023.02.001
-
Zhai, L., Wu, J., Lam, Y.Y., Kwan, H.Y., Bian, Z.-X. and Wong, H.L.X., 2021. Gut-Microbial Metabolites, Probiotics and Their Roles in Type 2 Diabetes. International Journal of Molecular Sciences 22(23): 12846. https://doi.org/10.3390/ijms222312846
-
Zhang, F., Aschenbrenner, D., Yoo, J.Y. and Zuo, T., 2022. The gut mycobiome in health, disease and clinical applications in association with the gut bacterial microbiome assembly. The Lancet Microbe 3(12): e969-e983. https://doi.org/10.1016/S2666-5247(22)00203-8
-
Zhang, J., Lei, H., Hu, X. and Dong, W., 2020. Hesperetin ameliorates DSS-induced colitis by maintaining the epithelial barrier via blocking RIPK3/MLKL necroptosis signaling. European Journal of Pharmacology 873: 172992. https://doi.org/10.1016/j.ejphar.2020.172992
-
Zhou, J., Li, M., Chen, Q., Li, X., Chen, L., Dong, Z., Zhu, W., Yang, Y., Liu, Z. and Chen, Q., 2022. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. Nature Communications 13(1): 3432. https://doi.org/10.1038/s41467-022-31171-0
Supplementary Materials
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 131 | 131 | 28 |
| Full Text Views | 3 | 3 | 0 |
| PDF Views & Downloads | 6 | 6 | 0 |
Investigating therapeutic efficacy of Lactobacillus salivarius GZLC1 on colitis by examining its effects on intestinal fungi, antioxidant capacity, and inflammatory response in mice
In: Beneficial MicrobesSearch for other papers by J. Ma in
Current site
Google Scholar
PubMed
Search for other papers by D. Wu in
Current site
Google Scholar
PubMed
Search for other papers by M. Liu in
Current site
Google Scholar
PubMed
Search for other papers by C. Xu in
Current site
Google Scholar
PubMed
Search for other papers by Q. He in
Current site
Google Scholar
PubMed
Search for other papers by M. Wang in
Current site
Google Scholar
PubMed
Search for other papers by F.A. Kiani in
Current site
Google Scholar
PubMed
Search for other papers by M.S. Rafiq in
Current site
Google Scholar
PubMed
Search for other papers by K. Mehmood in
Current site
Google Scholar
PubMed
Search for other papers by D. Fouad in
Current site
Google Scholar
PubMed
Search for other papers by F.S. Ataya in
Current site
Google Scholar
PubMed
Search for other papers by K. Li in
Current site
Google Scholar
PubMed
Abstract
We investigated the therapeutic potential of Lactobacillus salivarius in colitis mice, and the mice were randomly allocated into three groups with each consisting of 10 mice (n = 10): a control group (CSG), a DSS-induced colitis model group (DSG), and a L. salivarius intervention group (LSG). The intervention group received daily oral administration of L. salivarius for seven consecutive days. Compared to the DSS model group, mice receiving L. salivarius exhibited significantly reduced weight loss, lower DAI scores, lessened colon shortening, and improved histopathological profiles, indicating a substantial reduction in inflammatory damage. Additionally, ITS sequencing revealed that L. salivarius significantly influenced the composition of the intestinal fungal community, decreasing the abundance of pathogenic fungi, such as Candida species, by approximately 40%, and restoring fungal homeostasis by reducing the Basidiomycota/Ascomycota ratio. Moreover, L. salivarius effectively alleviated DSS-induced oxidative stress by lowering serum MDA levels while enhancing the activity of SOD and GSH-Px. Furthermore, the probiotic intervention resulted in 30-40% reduction in pro-inflammatory factors (TNF-α, IL-6, and IL-1β) and an increase in the anti-inflammatory factor IL-10 levels, suggesting a pronounced anti-inflammatory effect. In conclusion, L. salivarius exerts significant protective effects against DSS-induced colitis by modulating the gut fungal community, mitigating oxidative stress, and suppressing inflammatory responses. This study is novel in that few probiotic studies have investigated the impact of L. salivarius on gut fungi in DSS-induced colitis. These findings highlight its potential as a therapeutic candidate for managing inflammatory bowel disease.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 131 | 131 | 28 |
| Full Text Views | 3 | 3 | 0 |
| PDF Views & Downloads | 6 | 6 | 0 |
